TTY Competitors

Stocks . Taiwan . 
Stock . TTY Biopharm Co
4105 Stock  TWD 74.00  0.40  0.54%   
TTY Biopharm competes with Tehmag Foods, Ibase Gaming, Founding Construction, Hunya Foods, and ReaLy Development; as well as few others. The company operates under Healthcare sector and is part of Drug Manufacturers - Specialty & Generic industry. Analyzing TTY Biopharm competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of TTY Biopharm to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out TTY Biopharm Correlation with its peers.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of TTY Biopharm competition on your existing holdings.
  
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
73.5474.0074.46
Details
Intrinsic
Valuation
LowRealHigh
73.3973.8574.31
Details
Naive
Forecast
LowNextHigh
73.7874.2474.69
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
72.2873.4874.67
Details

TTY Biopharm Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between TTY Biopharm and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of TTY and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of TTY Biopharm does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
5533
+ 0.72
1264
1236
+ 0.69
1264
2596
+ 0.66
5533
1540
+ 0.65
1264
1236
+ 0.64
5533
6441
+ 0.62
1264
  
High negative correlations   
5515
- 0.92
1264
1540
- 0.67
5515
5515
- 0.59
6441
5515
- 0.57
5533
5515
- 0.55
1236
5515
- 0.28
2596

Risk-Adjusted Indicators

There is a big difference between TTY Stock performing well and TTY Biopharm Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze TTY Biopharm's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
All Fundamental Data

TTY Biopharm Competitive Analysis

The better you understand TTY Biopharm competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, TTY Biopharm's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across TTY Biopharm's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
4105 1264 6441 5533 1236 2596 5515 1540
 0.54 
 74.00 
TTY
 0.33 
 305.50 
Tehmag
 1.26 
 40.30 
Ibase
 0.95 
 20.90 
Founding
 0.43 
 23.15 
Hunya
 1.81 
 40.60 
ReaLy
 0.18 
 27.00 
Chien
 2.60 
 39.40 
Roundtop
Market Volatility
(90 Days Market Risk)
Very steady
Very steady
Very steady
Very steady
Very steady
Very steady
Not too volatile
Not too volatile
Market Performance
(90 Days Performance)
Very Weak
Very Weak
Very Weak
Very Weak
Very Weak
Very Weak
OK
Very Weak
Odds of Financial Distress
(Probability Of Bankruptcy)
Low
Low
Below Average
Low
Below Average
Low
Low
Low
Current Valuation
(Equity Enterprise Value)
Fairly Valued
Fairly Valued
Over Valued
Over Valued
Fairly Valued
Over Valued
Over Valued
Over Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Cautious Hold
Sell
Strong Sell
Strong Sell
Hold
Strong Sell
Strong Sell
Strong Sell
Current Ratio
2.73 X
3.24 X
1.88 X
2.11 X
1.76 X
N/A
3.27 X
3.71 X
Net Asset
9.3 B
4.26 B
2.67 B
13.11 B
3.46 B
3.54 B
8.35 B
1.52 B
Profit Margin
0.24 %
0.13 %
0.06 %
0.29 %
0.20 %
0.21 %
0.03 %
0.24 %
EBITDA
1.27 B
1.03 B
(60.04 M)
1.25 B
153.08 M
353.98 M
576.4 M
3.51 M
Operating Margin
0.26 %
0.19 %
(0.09) %
0.23 %
(0.01) %
0.25 %
0.05 %
0.14 %
Current Valuation
20.05 B
9 B
2.72 B
4.36 B
2.88 B
1.47 B
(778.91 M)
434.68 M
Price To Book
3.78 X
3.43 X
2.26 X
0.56 X
0.84 X
0.83 X
0.61 X
0.97 X
Five Year Return
3.58 %
4.51 %
4.16 %
3.40 %
N/A
N/A
5.97 %
6.31 %
Retained Earnings
N/A
N/A
N/A
4.32 B
358 M
N/A
1.4 B
285 M
Current Asset
N/A
N/A
N/A
10.01 B
720 M
N/A
7.39 B
1.2 B
Beta
0.35
0.27
0.51
0.16
0.81
0.39
0.46
0.3
Number Of Employees
31
14
21
19
10
7
32
86
Shares Outstanding
248.65 M
37.05 M
43.32 M
285.24 M
108.34 M
100 M
252 M
85.47 M
Cash Flow From Operations
1.26 B
684.06 M
(23.53 M)
767.18 M
165 M
1.11 B
576.39 M
(36.58 M)
Annual Yield
0.04 %
0.04 %
0 %
0.06 %
0.02 %
0.08 %
0.09 %
0.02 %
Total Debt
4.15 M
40.77 M
313.5 M
1.62 B
550 M
N/A
N/A
17.33 M
Return On Equity
0.21
0.23
0.042
0.2
0.18
0.0694
0.0328
0.078
Z Score
N/A
N/A
4.8
1.8
2.4
N/A
N/A
49.2
Return On Asset
0.0824
0.14
-0.0114
0.0634
-0.0049
0.0374
0.0186
0.0252
Book Value Per Share
21.97 X
75.29 X
24.16 X
31.70 X
27.08 X
20.73 X
18.84 X
16.11 X
Current Liabilities
N/A
N/A
N/A
4.49 B
638 M
N/A
2.1 B
296 M
Total Asset
9.3 B
4.26 B
2.67 B
13.11 B
3.46 B
3.54 B
8.35 B
1.52 B
Debt To Equity
19.30 %
1.50 %
1.29 %
85.50 %
33.00 %
N/A
23.10 %
0.20 %
Target Price
75.0
N/A
N/A
N/A
N/A
N/A
18.3
N/A
Last Dividend Paid
3.0
12.0
N/A
1.0
0.5
1.5
1.02
0.3
Shares Owned By Institutions
17.40 %
2.94 %
N/A
2.88 %
N/A
N/A
1.42 %
N/A
Market Capitalization
19.37 B
9.95 B
2.8 B
4.93 B
2.55 B
1.91 B
2.89 B
1.44 B
Price To Earning
13.04 X
15.88 X
125.08 X
25.40 X
1.04 X
N/A
15.03 X
9.39 X
Price To Sales
4.10 X
1.81 X
3.95 X
0.87 X
1.19 X
2.16 X
0.57 X
3.09 X
Net Income
831.89 M
599.73 M
(122.49 M)
1.06 B
(27.36 M)
304.71 M
405.15 M
(3.62 M)
Earnings Per Share
4.79 X
17.64 X
0.79 X
5.76 X
3.68 X
1.71 X
0.60 X
1.22 X
Shares Owned By Insiders
20.58 %
36.29 %
47.25 %
52.31 %
62.24 %
57.49 %
44.99 %
31.58 %
Revenue
4.54 B
4.95 B
1.53 B
3.77 B
1.76 B
1.48 B
5.33 B
360.79 M
Working Capital
N/A
N/A
N/A
5.52 B
82 M
N/A
5.29 B
908 M
Cash And Equivalents
2.89 B
1.27 B
506.89 M
544.65 M
83.55 M
N/A
2.67 B
1.02 B
Cash Per Share
11.63 X
37.65 X
13.14 X
1.91 X
0.77 X
N/A
8.00 X
11.94 X
Gross Profit
2.77 B
1.79 B
102.8 M
1.08 B
452.29 M
488.18 M
624.37 M
58.31 M
Day Typical Price
74.2
305.67
40.32
20.98
23.18
40.53
27.1
39.97
Accumulation Distribution
2779.71
20.1
4555.44
2901.75
24.98
3812.26
9883.15
2.1 M
Daily Balance Of Power
(0.67)
2.0
0.303
(0.57)
(1.00)
(0.62)
(0.08)
0.2857
Period Momentum Indicator
(0.40)
1.0
0.5
(0.20)
(0.10)
(0.75)
(0.05)
1.0
Rate Of Daily Change
0.99
1.0
1.01
0.99
1.0
0.98
1.0
1.03
Day Median Price
74.3
305.75
40.33
21.03
23.2
40.5
27.15
40.25
Price Action Indicator
(0.50)
0.25
0.22
(0.23)
(0.10)
(0.27)
(0.18)
(0.35)
Relative Strength Index
53.28
25.86
29.51
49.23
39.34
54.96
63.18
34.88
Coefficient Of Variation
4956.14
(584.43)
(2,156)
(2,078)
(769.65)
(2,508)
969.74
2923.53
Mean Deviation
0.3223
0.2942
1.54
0.9806
0.524
1.71
1.58
2.73
Jensen Alpha
(0.02)
(0.08)
(0.07)
(0.05)
(0.14)
(0.14)
0.3492
0.0908
Total Risk Alpha
(0.07)
(0.13)
(0.50)
(0.29)
(0.21)
(0.48)
(0.17)
(0.50)
Sortino Ratio
(0.22)
N/A
N/A
N/A
N/A
N/A
0.0768
0.0017
Downside Variance
0.3062
N/A
N/A
N/A
N/A
N/A
5.07
8.79
Standard Deviation
0.4556
0.3799
2.43
1.34
0.7096
2.4
2.94
3.96
Kurtosis
2.73
0.3805
6.66
2.63
1.46
3.44
12.62
1.54
Potential Upside
0.6831
0.6339
3.2
1.7
1.06
3.38
4.04
9.91
Treynor Ratio
(0.01)
(9.26)
0.2957
0.427
(0.34)
(0.36)
(0.63)
0.436
Maximum Drawdown
2.55
1.59
18.65
6.41
3.26
13.35
23.1
18.19
Variance
0.2076
0.1443
5.89
1.8
0.5036
5.77
8.66
15.68
Market Risk Adjusted Performance
0.0033
(9.25)
0.3057
0.437
(0.33)
(0.35)
(0.62)
0.446
Risk Adjusted Performance
0.0086
(0.14)
(0.03)
(0.03)
(0.10)
(0.02)
0.0862
0.0342
Skewness
(0.71)
0.2885
0.1615
(1.12)
(0.02)
(0.97)
2.41
1.15
Semi Deviation
0.4289
N/A
N/A
N/A
N/A
N/A
1.65
2.68
Information Ratio
(0.27)
(0.51)
(0.10)
(0.15)
(0.31)
(0.09)
0.0588
0.0013
Value At Risk
(0.68)
(0.65)
(3.33)
(2.60)
(1.21)
(4.29)
(3.25)
(4.09)
Expected Short fall
(0.40)
N/A
N/A
N/A
N/A
N/A
(2.37)
(4.05)
Downside Deviation
0.5533
N/A
N/A
N/A
N/A
N/A
2.25
2.96
Semi Variance
0.184
N/A
N/A
N/A
N/A
N/A
2.74
7.19

TTY Biopharm Competition Performance Charts

Five steps to successful analysis of TTY Biopharm Competition

TTY Biopharm's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by TTY Biopharm in relation to its competition. TTY Biopharm's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of TTY Biopharm in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact TTY Biopharm's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to TTY Biopharm, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your TTY Biopharm position

In addition to having TTY Biopharm in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run FinTech Thematic Idea Now

FinTech
FinTech Theme
High long term potential financial entities that are ranging from payment processing, investment management to commercial and investment banking. The FinTech theme has 81 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize FinTech Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for TTY Stock Analysis

When running TTY Biopharm's price analysis, check to measure TTY Biopharm's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TTY Biopharm is operating at the current time. Most of TTY Biopharm's value examination focuses on studying past and present price action to predict the probability of TTY Biopharm's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TTY Biopharm's price. Additionally, you may evaluate how the addition of TTY Biopharm to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY